Serelaxin Rejection Shows “Breakthrough” Status Doesn’t De-Risk Programs
This article was originally published in Pharmaceutical Approvals Monthly
FDA “complete response” appears to be the first for a product under the expedited pathway. But Novartis has a second trial that could support resubmission in 2016, and two other late-stage heart failure drugs in the pipeline.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.